Sisram Medical's Profhilo Registered for Facial Treatments in China

Sisram Medical Ltd, a prominent name in the global wellness sector, has made a significant leap in expanding its medical aesthetics offerings by announcing the acceptance of its registration application for Profhilo in China. This approval, granted by the National Medical Products Administration (NMPA), paves the way for a more robust presence in the region as the company seeks to introduce this innovative injectable into the Chinese market.

Profhilo stands out as a high-concentration sodium hyaluronate injectable that boasts a BDDE-free formulation. Developed through Sisram's patented NAHYCO® technology, Profhilo is designed to deeply hydrate the skin and promote biostimulation, which in turn encourages the production of collagen and elastin. The primary goal of Profhilo is to improve skin texture, firmness, and elasticity, making it a compelling choice for consumers seeking effective skin rejuvenation solutions.

With its proven track record in international markets like Israel, India, and Thailand, Sisram Medical has established a foothold with Profhilo across various regions. This injectable has been well-received by leading medical aesthetics clinics and practitioners, particularly in Thailand, where it has seen substantial growth. By integrating Profhilo with its popular Soprano series of Energy-Based Devices (EBD), Sisram has crafted unique combination treatment protocols that enhance patient outcomes through synergistic effects of the treatments.

The acceptance of the registration application is not just a mere formality; it is a strategic move for Sisram as it positions itself for a successful launch in China, a rapidly growing market for medical aesthetic procedures. The company has proactively initiated a comprehensive strategy encompassing market positioning, channel strategy, medical education, and operational planning to facilitate a smooth introduction of Profhilo. By leveraging its extensive customer network in China, coupled with its experience in developing localized operations and support systems for premium injectables, Sisram is laying solid groundwork for penetrating the market effectively.

Mr. Jiahong Li, Co-CEO and CFO of Sisram, expressed optimism regarding this milestone, noting that the acceptance by the NMPA signifies a crucial step for Sisram's injectables business in China. Furthermore, he emphasized the company's approach to carefully expand into key markets through its global portfolio.

The coming months will see Sisram advancing its regulatory review for Profhilo while continuing its preparation for commercialization. This dual-track approach will allow for an efficient transition from approval to market entry, strengthened by Sisram's existing distribution network and product portfolio.

Sisram Medical's commitment to innovation and quality positions it favorably within the competitive landscape of China's medical aesthetics market. As it seeks to broaden its offerings and enhance its product lineup, the company is well-poised to capitalize on the growing demand for quality medical aesthetics solutions in the region. By fostering closer integration between its EBD and injectables businesses, Sisram aims to deliver unparalleled treatment options that enhance both patient satisfaction and procedural efficacy.

As Sisram continues to evolve its portfolio and expand commercial capabilities, it aims to solidify its standing as a leader in the medical aesthetics industry, supporting sustainable growth in the long term and fulfilling the ever-evolving needs of consumers worldwide.

About Sisram Medical Ltd

With a history spanning over 25 years, Sisram Medical Ltd (1696.HK), majority-owned by Fosun Pharma, specializes in medical aesthetic solutions, particularly in Energy-Based Devices (EBD). The company has set new benchmarks in safety and efficacy, serving clients in over 110 countries. It became listed on the Main Board of the Hong Kong Stock Exchange in September 2017, continuing its legacy of innovation within the medical aesthetics field.